Effect of dendritic cell/cytokine-induced killer cell immunobiological cancer therapy combined with adjuvant chemotherapy in patients with triple-negative breast cancer

查看全文 作　　者：Ranran [1,2]Zhang;Wanqing [3]Xie;Tao [2]Han;Yongye [2]Liu;Zhaozhe [2]Liu;Fang [2]Guo;Yaling [2]Han;Zhenyu [2]Ding;Yinghui [4]Sun;Dongchu [4]Ma;Xiaodong [2]Xie

机构地区：[1]Liaoning Medical University;[2]Department of Oncology, Cancer center, General Hospital of Shenyang Military Region;[3]Molecular Biology Laboratory of Traditional Chinese Medicine, The Basic Medical College of Liaoning University of Traditional Chinese Medicine;[4]Department of Experimental Medicine, Cancer center, General Hospital of Shenyang Military Region

出　　处：《The Chinese-German Journal of Clinical Oncology》索引2015年第14卷第1期,共5页

基　　金：Supported by grants from the National Research Key Project of the Twelfth Five-Year Plan of the Republic of China(No.012ZX09303016-002);Liaoning Province Science&Technology Development Funds(No.2012225019) 摘　　要：Objective The aim of the present study was to investigate the effect of dendritic cell(DC)/cytokine-induced killer cell(CIK) immunobiological cancer therapy in patients with triple-negative breast cancer(TNBC) who underwent adjuvant chemotherapy. Methods From January 2010 to October 2013, 120 patients with postoperative TNBC were recruited and included in the study. Patients were enrolled in one of two groups according to whether they accepted DC/CIK immunobiological cancer therapy during adjuvant chemotherapy; the patients in the DC/CIK group underwent adjuvant chemotherapy combined with DC/CIK immunobiological cancer therapy, and the control group underwent adjuvant chemotherapy alone. When six cycles of adjuvant chemotherapy and six cycles of DC/CIK immunobiological cancer therapy had been completed, differences between the two groups with regard to quality of life(Qo L), immunological indicators(CD3, CD4, CD8, and NK cell levels), disease-free survival(DFS), and side effects of chemotherapy and DC/CIK treatment were evaluated.Results In the DC/CIK group, the proportion of NK cells and CD3+ and CD4+ T-cell subgroups significantly increased, and the proportion of CD8+ cells decreased when they were compared before and after DC/CIK therapy(P < 0.05). However, there were no significant changes in the control group. By the final follow-up, DFS of the treatment group and the control group was 38.4 and 34.2 months, respectively. The Qo L improved in the patients treated with chemotherapy plus DC/CIK therapy compared with the patients treated with chemotherapy alone, and the difference between groups was significant(P < 0.05). The side effects of two groups were tolerable and not significantly different between the two groups.Conclusion The DC/CIK treatment had potential benefits for patients with TNBC compared with the control group, and was not associated with any obvious side effects. Therefore, DC/CIK therapy is a safe and effective method for the treatment of TNBC. 关键词：生物治疗癌症患者细胞免疫树突状细胞细胞因子杀伤细胞乳腺癌化疗

相关文献

参考文献（12）
引证文献（2）
耦合文献（50）

参考文献(12)

引证文献(2)

耦合文献(50)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Effect of dendritic cell/cytokine-induced killer cell immunobiological cancer therapy combined with adjuvant chemotherapy in patients with triple-negative breast cancer

参考文献(12)

引证文献(2)

耦合文献(50)

用户提示